Printer Friendly

Ranbaxy brings pain to Daiichi.

Summary: Tokyo: Daiichi Sankyo believed it had scored a coup in 2008 when it outbid rivals ...

Tokyo: Daiichi Sankyo believed it had scored a coup in 2008 when it outbid rivals to buy Indian generics giant Ranbaxy for $4.6 billion but its foray into the high-growth copycat drugs arena has brought the Japanese drugmaker only pain. Last month, Ranbaxy pleaded guilty to United States charges of selling adulterated antibiotic, acne, epilepsy and other drugs and agreed to a record $500 million fine, and since then the bad news has kept on flowing. In a new blow at the end of the week, Apollo Pharmacy, India's biggest branded drug retail network with more than 1,500 outlets, issued a 'cautionary advisory' against drugs made by Ranbaxy. A Ranbaxy spokesman insisted all its products in India and globally were 'safe and efficacious' and that it was addressing Apollo's concerns.

Muscat Press and Publishing House SAOC 2013

Provided by Syndigate.info an Albawaba.com company
COPYRIGHT 2013 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Times of Oman (Muscat, Oman)
Date:Jun 9, 2013
Words:163
Previous Article:Travelex's new service to benefit Oman expats.
Next Article:MSM index ends higher.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters